This study aims to determine whether Ropivacaine-Poloxamer 407 hydrogel provides non-inferior pain control compared to TAP block for patients undergoing minimally invasive gastrectomy. The results will guide postoperative pain management practices and enhance recovery protocols for gastric cancer surgery.
Patients with a histologically confirmed diagnosis of gastric adenocarcinoma prior to surgery.
Patients who have undergone a complete surgical resection (R0 resection).
Patients with an ASA (American Society of Anesthesiologists) score of 3 or below.
Patients aged 20 years or older.
Patients under 19 years of age.
Presence of ascites or peritoneal metastasis.
Patients who have undergone preoperative chemotherapy or radiotherapy.
Diagnosis of malignancies other than gastric cancer.